{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.470","upperLimit":"7.424","value":"3.95"},{"groupId":"OG001","lowerLimit":"6.538","upperLimit":"14.329","value":"10.43"}]}],"title":"SBP"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.199","upperLimit":"5.928","value":"2.86"},{"groupId":"OG001","lowerLimit":"3.224","upperLimit":"9.832","value":"6.53"}]}],"title":"DBP"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"Blood pressure was measured by 24-hour ABPM.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients who meet any of the response criteria will advance to the RW Phase of the study and receive the same dose of relacorilant as the last dose administered in the OL Phase.\n\nRelacorilant: Relacorilant is supplied as 100 mg capsules for oral dosing.","id":"OG000","title":"Relacorilant (RW Phase)"},{"description":"Patients who meet any of the response criteria will advance to the RW Phase of the study and receive placebo matched to study drug.\n\nPlacebo: Placebo matched to study drug","id":"OG001","title":"Placebo (RW Phase)"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The analysis population was patients in the ITT-RW Population who had HTN with or without DM/IGT at Baseline.","reportingStatus":"POSTED","timeFrame":"Week 22 (end of OL Phase) and Week 36 (Week 12 of RW Phase)","title":"Change in SBP and DBP During the RW Phase","type":"SECONDARY","unitOfMeasure":"mm Hg"}